Double hit lymphoma: the MD Anderson Cancer Center clinical experience
暂无分享,去创建一个
Michael L. Wang | Y. Oki | F. Turturro | L. Medeiros | L. Kwak | Y. Nieto | C. Pinnix | L. Fayad | J. Westin | S. Neelapu | P. Lin | R. Davis | B. Dabaja | H. Lee | M. Fanale | F. Hagemeister | I. Khouri | J. Romaguera | F. Samaniego | L. Nastoupil | N. Fowler | M. Ahmed | M. Noorani | Maria Alma Rodriguez | Long Ma | M. Rodriguez | M. Ahmed
[1] Michael L. Wang,et al. Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma , 2013, British journal of haematology.
[2] J. Friedberg,et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. , 2013, The New England journal of medicine.
[3] J. Friedberg. Double-hit diffuse large B-cell lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Medeiros,et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome , 2012, Modern Pathology.
[5] Philip M Kluin,et al. Double-hit B-cell lymphomas. , 2011, Blood.
[6] Matija Snuderl,et al. B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma , 2010, The American journal of surgical pathology.
[7] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[8] N. Nakamura,et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations , 2009, Haematologica.
[9] I. Miura,et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations , 2009, Leukemia.
[10] L. Staudt,et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[12] P. Moreau,et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement , 2007, Haematologica.
[13] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] F. Jardin,et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.
[15] L. Medeiros,et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis , 2006, Modern Pathology.
[16] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[17] L. Staudt,et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. , 2002, Blood.
[18] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[19] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[20] J. Fine,et al. Regression modeling of competing crude failure probabilities. , 2001, Biostatistics.
[21] R. Gascoyne,et al. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[24] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[25] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[26] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .